Understanding Shifting Toward Precision Care In Ms Using Disease Activity Tests And Serum Biomarkers
If you are looking for information about Shifting Toward Precision Care In Ms Using Disease Activity Tests And Serum Biomarkers, you have come to the right place. In the clinical management of
Key Takeaways about Shifting Toward Precision Care In Ms Using Disease Activity Tests And Serum Biomarkers
- Considering the complex pathology of
- Ferhan Qureshi, BS, Vice President, Octave Bioscience, Menlo Park, CA, describes the results of a study evaluating the ...
- CME Outfitters presents a 3-part series of podcasts that will examine and translate the emerging data to practice. Part 1 will ...
- Chair and Moderator, Jiwon Oh, MD, PhD, FRCPC, Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, and Kathleen M. Costello, ...
- Ferhan Qureshi, SVP -
Detailed Analysis of Shifting Toward Precision Care In Ms Using Disease Activity Tests And Serum Biomarkers
Jens Kuhle, MD, PhD, University Hospital and University of Basel, Basel, Switzerland, shares an overview of the established ... The conventional monitoring for Shane Arsenault, MD, Memorial University of Newfoundland, St. John's, Canada, discusses future work on
Biomarker testing
We hope this detailed breakdown of Shifting Toward Precision Care In Ms Using Disease Activity Tests And Serum Biomarkers was helpful.